Icatibant
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 768 publications
Advances in pharmacotherapy for children aged 2 to <12 years with hereditary angioedema: what is the current state of play?
Journal: Expert opinion on pharmacotherapy
Published: October 28, 2026
Development and validation of an RP-HPLC method for the quantification of impurities of icatibant injection in finished formulations-identification and characterization of its impurities via LC-HRMS.
Journal: European journal of mass spectrometry (Chichester, England)
Published: September 30, 2026
Bradykinin B2 receptor triggers ITPR1-Mediated ER calcium release in trigeminal ganglion neurons to drive trigeminal neuropathic pain.
Journal: Molecular pain
Published: July 15, 2026
Isolated gastrointestinal hereditary angioedema associated with a pathogenic SERPING1 variant arising de novo: a case report.
Journal: Frontiers in medicine
Published: July 13, 2026
Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review.
Journal: Allergy and asthma proceedings
Published: June 25, 2026
Chronic Spontaneous Urticaria with Biochemical C1 Inhibitor Deficiency: A Case Report of Suspected Overlap with Hereditary Angioedema.
Journal: Clinical, cosmetic and investigational dermatology
Published: June 23, 2026
Recurrent abdominal attacks as a presentation of hereditary angioedema type I: a multigenerational family series.
Journal: Revista espanola de enfermedades digestivas
Published: June 10, 2026
Current and future therapies for bradykinin-mediated angioedema
Journal: Dermatologie (Heidelberg, Germany)
Published: May 27, 2026
First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: May 24, 2026
First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: May 24, 2026
Last Updated: 11/08/2026